Dermata Therapeutics, Inc. (DRMA)

NASDAQ: DRMA · IEX Real-Time Price · USD
0.411
+0.011 (2.70%)
At close: Mar 28, 2024, 4:00 PM
0.417
+0.006 (1.39%)
After-hours: Mar 28, 2024, 7:25 PM EDT
2.70%
Market Cap 1.43M
Revenue (ttm) n/a
Net Income (ttm) -7.79M
Shares Out 6.66M
EPS (ttm) -2.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 36,983
Open 0.410
Previous Close 0.400
Day's Range 0.395 - 0.417
52-Week Range 0.370 - 3.930
Beta 0.87
Analysts n/a
Price Target n/a
Earnings Date Mar 21, 2024

About DRMA

Dermata Therapeutics, Inc., a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also develo... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 13, 2021
Employees 8
Stock Exchange NASDAQ
Ticker Symbol DRMA
Full Company Profile

Financial Performance

Financial Statements

News

Dermata to Present at the Emerging Growth Conference on April 3, 2024

- Dermata to provide a corporate update followed by a live question and answer session - SAN DIEGO, CA / ACCESSWIRE / March 27, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the...

1 day ago - Accesswire

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

- Initiated enrollment of DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial in Q4 2023 - - Raised $9.1 million in gross proceeds from three financings completed in 2023 - - R...

7 days ago - Accesswire

Dermata to Present at the Emerging Growth Conference on February 7, 2024

- Company to provide a corporate overview followed by a live question and answer session - SAN DIEGO, CA / ACCESSWIRE / February 1, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Derm...

2 months ago - Accesswire

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

- This is the Company's first patent issued for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company is currently discussing partnership opport...

3 months ago - Accesswire

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

- About 550 patients will be treated once weekly for 12 weeks - - STAR-1 topline results expected in first quarter of 2025 - - Acne affects about 50 million patients in the U.S. - SAN DIEGO, CA / ACCE...

3 months ago - Accesswire

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment o...

4 months ago - Accesswire

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

- DMT310 Phase 3 STAR-1 (Spongilla Treatment of Acne Research) clinical trial will evaluate the efficacy and safety of once-weekly treatments of DMT310 for 12 weeks in moderate-to-severe acne patients...

4 months ago - Accesswire

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

- Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 - - Received positive feedback from FDA on its End of Phase 2 meeting package in June 2023 - - Complete...

5 months ago - Accesswire

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

- Dermata is prepared to initiate DMT310 Phase 3 STAR-1 clinical trial by the end of 2023 - - Investigational sites have been selected - - Clinical trial materials are ready to be shipped to investiga...

5 months ago - Accesswire

Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference

SAN DIEGO, CA / ACCESSWIRE / August 31, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical...

7 months ago - Accesswire

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

- Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 - - Received positive feedback on its End of Phase 2 meeting package from FDA in June 2023 - - Phase 3 ...

8 months ago - Accesswire

Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne

- FDA established key elements of the DMT310 Phase 3 clinical program and delineated a potential regulatory pathway for approval of DMT310 - -The DMT310 Phase 3 program will consist of two pivotal tri...

9 months ago - Accesswire

Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

SAN DIEGO, CA / ACCESSWIRE / June 13, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical a...

10 months ago - Accesswire

Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results

- DMT310 once-weekly topical treatment demonstrated statistically significant improvements at all time points in the three primary endpoints, inflammatory lesion count, noninflammatory lesion count, a...

10 months ago - Accesswire

Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESSWIRE / May 26, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical a...

10 months ago - Accesswire

Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE / May 24, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasda...

11 months ago - Accesswire

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

- Dermata raised $5 million gross proceeds from a public offering in March 2023 - - Dermata submitted an End of Phase 2 meeting package to FDA in April 2023 - - FDA agreed that Dermata's chemistry, ma...

11 months ago - Accesswire

Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package

- FDA agrees that Dermata's CMC procedures and controls support the initiation of Phase 3 studies- - Dermata also submitted an end of phase 2 meeting package to the FDA - SAN DIEGO, CA / ACCESSWIRE / ...

1 year ago - Accesswire

Dermata Therapeutics Announces Closing of $5.0 Million Public Offering

SAN DIEGO, CA / ACCESSWIRE / March 20, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of ...

1 year ago - Accesswire

Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering

SAN DIEGO, CA / ACCESSWIRE / March 16, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical...

1 year ago - Accesswire

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results

- End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 - - Initiation of DMT310 Phase 3 clinical trial program in moderate-to-severe acne patients expected in 2H ...

1 year ago - Accesswire

Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea

- Data supportive of DMT310 as a treatment for inflammatory skin diseases, but rosacea study did not meet primary endpoints - - DMT310 produced no serious adverse events related to treatment - - Derma...

1 year ago - Accesswire

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

- DMT310 Phase 2 topline results in moderate-to-severe rosacea anticipated in December 2022 - - Initiation of DMT310 Phase 3 for moderate-to-severe acne expected in 1H 2023 - SAN DIEGO, CA / ACCESSWIR...

1 year ago - Accesswire

Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SAN DIEGO, CA / ACCESSWIRE / September 6, 2022 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and ...

1 year ago - Accesswire

Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase

SAN DIEGO, CA / ACCESSWIRE / August 24, 2022 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and a...

1 year ago - Accesswire